Literature DB >> 32887999

Déjà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures-Same Satisfactory Results, Same Unanswered Questions.

Mark Sulkowski1, David Wyles2.   

Abstract

Entities:  

Keywords:  Direct Acting Antivirals; hepatitis C; resistance associated substitutions; retreatment

Mesh：

Substances：

Year:  2021        PMID： 32887999      PMCID： PMC8563175          DOI： 10.1093/cid/ciaa1329

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


× No keyword cloud information.
  22 in total

1.  Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.

Authors:  Kosh Agarwal; Lluís Castells; Beat Müllhaupt; William M C Rosenberg; Brian McNabb; Sarah Arterburn; Gregory Camus; John McNally; Luisa M Stamm; Diana M Brainard; G Mani Subramanian; Zoe Mariño; Jean-François Dufour; Xavier Forns
Journal:  J Hepatol       Date:  2018-06-08       Impact factor: 25.083

2.  Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.

Authors:  Jordi Llaneras; Mar Riveiro-Barciela; Sabela Lens; Moisés Diago; Alba Cachero; Javier García-Samaniego; Isabel Conde; Ana Arencibia; Juan Arenas; Francisco Gea; Xavier Torras; José Luis Calleja; José Antonio Carrión; Inmaculada Fernández; Rosa María Morillas; José Miguel Rosales; Isabel Carmona; Conrado Fernández-Rodríguez; Manuel Hernández-Guerra; Susana Llerena; Vanesa Bernal; Juan Turnes; Jesús M González-Santiago; Silvia Montoliu; Blanca Figueruela; Ester Badia; Manuel Delgado; Miguel Fernández-Bermejo; Mercedes Iñarrairaegui; Juan Manuel Pascasio; Rafael Esteban; Zoe Mariño; Maria Buti
Journal:  J Hepatol       Date:  2019-06-14       Impact factor: 25.083

Review 3.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-03-27

4.  Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.

Authors:  Edward J Gane; Mitchell L Shiffman; Kyle Etzkorn; Giuseppe Morelli; Catherine A M Stedman; Mitchell N Davis; Federico Hinestrosa; Hadas Dvory-Sobol; K C Huang; Anu Osinusi; John McNally; Diana M Brainard; John G McHutchison; Alex J Thompson; Mark S Sulkowski
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

5.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Authors:  Christophe Hézode; Nicole Forestier; Geoffrey Dusheiko; Peter Ferenci; Stanislas Pol; Tobias Goeser; Jean-Pierre Bronowicki; Marc Bourlière; Shahin Gharakhanian; Leif Bengtsson; Lindsay McNair; Shelley George; Tara Kieffer; Ann Kwong; Robert S Kauffman; John Alam; Jean-Michel Pawlotsky; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

6.  Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.

Authors:  Pamela S Belperio; Troy A Shahoumian; Timothy P Loomis; Lisa I Backus
Journal:  J Viral Hepat       Date:  2019-05-10       Impact factor: 3.728

7.  Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.

Authors:  Nancy Reau; Paul Y Kwo; Susan Rhee; Robert S Brown; Kosh Agarwal; Peter Angus; Edward Gane; Jia-Horng Kao; Parvez S Mantry; David Mutimer; K Rajender Reddy; Tram T Tran; Yiran B Hu; Abhishek Gulati; Preethi Krishnan; Emily O Dumas; Ariel Porcalla; Nancy S Shulman; Wei Liu; Suvajit Samanta; Roger Trinh; Xavier Forns
Journal:  Hepatology       Date:  2018-07-25       Impact factor: 17.425

8.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Authors:  Michael P Curry; Jacqueline G O'Leary; Natalie Bzowej; Andrew J Muir; Kevin M Korenblat; Jonathan M Fenkel; K Rajender Reddy; Eric Lawitz; Steven L Flamm; Thomas Schiano; Lewis Teperman; Robert Fontana; Eugene Schiff; Michael Fried; Brian Doehle; Di An; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Robert S Brown; Michael Charlton
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

9.  Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.

Authors:  Christoph Sarrazin; Hadas Dvory-Sobol; Evguenia S Svarovskaia; Brian P Doehle; Phillip S Pang; Shu-Min Chuang; Julie Ma; Xiao Ding; Nezam H Afdhal; Kris V Kowdley; Edward J Gane; Eric Lawitz; Diana M Brainard; John G McHutchison; Michael D Miller; Hongmei Mo
Journal:  Gastroenterology       Date:  2016-06-11       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.